BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29044514)

  • 1. CCDC6: the identity of a protein known to be partner in fusion.
    Cerrato A; Merolla F; Morra F; Celetti A
    Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
    Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
    Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
    Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
    Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
    Laxmi A; Gupta P; Gupta J
    Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
    Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
    Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.
    Cerrato A; Morra F; Di Domenico I; Celetti A
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic perspectives in CCDC6 deficient lung cancer cells.
    Morra F; Luise C; Visconti R; Staibano S; Merolla F; Ilardi G; Guggino G; Paladino S; Sarnataro D; Franco R; Monaco R; Zitomarino F; Pacelli R; Monaco G; Rocco G; Cerrato A; Linardopoulos S; Muller MT; Celetti A
    Int J Cancer; 2015 May; 136(9):2146-57. PubMed ID: 25302833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
    Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
    J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
    Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
    PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of CCDC6 reduces the expression of 14-3-3σ in colorectal carcinoma cells.
    Thanasopoulou A; Xanthopoulou AG; Anagnostopoulos AK; Konstantakou EG; Margaritis LH; Papassideri IS; Stravopodis DJ; Tsangaris GT; Anastasiadou E
    Anticancer Res; 2012 Mar; 32(3):907-13. PubMed ID: 22399611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of
    Mejia Saldarriaga M; Steinberg A; Severson EA; Binder A
    Front Oncol; 2019; 9():1303. PubMed ID: 31850206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.
    Leone V; Mansueto G; Pierantoni GM; Tornincasa M; Merolla F; Cerrato A; Santoro M; Grieco M; Scaloni A; Celetti A; Fusco A
    Oncogene; 2010 Jul; 29(30):4341-51. PubMed ID: 20498639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
    Luise C; Merolla F; Leone V; Paladino S; Sarnataro D; Fusco A; Celetti A
    PLoS One; 2012; 7(11):e49298. PubMed ID: 23145146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene rearrangements in radiation-induced thyroid carcinogenesis.
    Rabes HM
    Med Pediatr Oncol; 2001 May; 36(5):574-82. PubMed ID: 11340615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adversary of DNA integrity: A long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells.
    Demin DE; Murashko MM; Uvarova AN; Stasevich EM; Shyrokova EY; Gorlachev GE; Zaretsky AR; Korneev KV; Ustiugova AS; Tkachenko EA; Kostenko VV; Tatosyan KA; Sheetikov SA; Spirin PV; Kuprash DV; Schwartz AM
    Int J Cancer; 2023 Apr; 152(7):1452-1462. PubMed ID: 36510744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.
    Zhao J; Xu W; Zhuo X; Liu L; Zhang J; Jiang F; Shen Y; Lei Y; Hou D; Lin X; Wang C; Fu G
    Oncologist; 2023 May; 28(6):e416-24. PubMed ID: 37141396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
    Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
    Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma.
    Ciampi R; Giordano TJ; Wikenheiser-Brokamp K; Koenig RJ; Nikiforov YE
    Endocr Relat Cancer; 2007 Jun; 14(2):445-52. PubMed ID: 17639057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.